<DOC>
	<DOCNO>NCT02018965</DOCNO>
	<brief_summary>There number powerful anti-HIV drug , keep virus undetectable level enable HIV-infected individual live longer . However , participant take anti-HIV drug achieve adequate CD4 recovery remain risk develop AIDS non-AIDS-related complication . ER niacin ( PrNiaspanFCT® ) extended-released form niacin , also know vitamin B3 . Niacin effective reduce cholesterol level blood . This drug know long-time treat dyslipidemia use improve favourably lipoprotein risk factor artherosclerotic disease , particularly HIV-infected patient . Recent scientific research show regular consumption niacin-rich food may also provide protection Alzheimer 's disease age-related cognitive decline . The purpose study find : 1 . If ER niacin combine anti-HIV drug , compare anti-HIV drug alone , could reduce T cell immune activation enhance CD4 recovery ; 2 . If ER niacin improve quality life neurocognitive function</brief_summary>
	<brief_title>Niacin Immune Activation : Proof-of-concept Study</brief_title>
	<detailed_description>Primary objective • To assess impact extended-release niacin ( ER niacin ) supplementation + antiretroviral therapy ( ART ) compare ART alone T-cell immune activation define CD8CD38 percentage Secondary objectives - To assess change total CD4 T-cell count ER niacin administration - To explore effect ER niacin regulatory T-cells ( Th-17/Treg ) blood gut mucosa sample - To explore effect ER niacin cytokine inflammatory marker INF-α , IL-1 , IL-6 , IL-17 , D-dimers , usCRP LPS - To assess influence ER niacin tryptophan ( Trp ) plasmatic level - To assess change cholesterol triglycerides - To explore ER niacin tolerance - To evaluate impact ER niacin quality life ( QoL ) , fatigue , depression , neurocognitive score Population : All participant undetectable HIV viral load ( &lt; 50 copies/mL ) least 3 month , current CD4 cell count &lt; 350 cells/µL receive ART least previous 12 month . Sample size : N=20</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Participants must meet follow criterion within four week prior Week 0 ( Baseline ) Visit consider eligible entry study : 1 . Documented HIV infection Western Blot , EIA assay viral load assay 2 . Aged 21 old 3 . Viral load &lt; 50 copies/mL last 3 month 4 . CD4 cell count &lt; 350 cells/µL 5 . On stable ART , i.e. , ART unchanged treatment failure ( rebound viral load ) 12 month 6 . Able communicate adequately either French English 7 . Able willing give write informed consent prior enrolment include access relevant medical record . Participants eligible participate study follow condition meet : 1 . Pregnant , breastfeed plan become pregnant course study . All fecund female participant must undergo pregnancy test , negative result , prior eligible participate study 2 . Prior history hypersensitivity reaction niacin component study drug 3 . Prior history flush 4 . Active liver disease unexplained persistent elevation serum transaminases 5 . Coinfection active Hepatitis B C virus ( positive HBs Ag positive anti HBc antibodies detectable HBV DNA viral load positive anti HCV antibodies detectable HCV RNA viral load ) 6 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) alkaline phosphatase &gt; 2.5 x upper limit normal ( ULN ) 7 . Active duodenal gastric peptic ulcer 8 . Active bleeding disorder 9 . History gout 10 . Active AIDS event last 3 month determine treat physician 11 . Unstable angina acute phase myocardial infarction , without vasodilator agent 12 . Diabetic potentially diabetic hypercholesterolaemia 13 . Renal dysfunction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Extended-release Niacin</keyword>
	<keyword>Immune activation</keyword>
</DOC>